BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
Biomolecules · 2024
DOI: 10.3390/biom14060625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Sushmitha Sriramulu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI 48202, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Phthalazines, Cisplatin, Piperazines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Henry Ford Cancer Institute, Henry Ford Health.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BUB1 is overexpressed in most human solid cancers, including breast cancer. Higher BUB1 levels are associated with a poor prognosis, especially in patients with triple-negative breast cancer (TNBC). Women with TNBC often develop resistance to chemotherapy and radiotherapy, which are still the mainstay of treatment for TNBC. Our previous studies demonstrated that a BUB1 kinase inhibitor (BAY1816032) reduced tumor cell proliferation and significantly enhanced radiotherapy efficacy in TNBC. In this study, we evaluated the effectiveness of BAY1816032 with a PARP inhibitor (olaparib), platinum agent (cisplatin), and microtubule poison (paclitaxel) alone or in combination with radiotherapy using cytotoxicity and clonogenic survival assays. BUB1 inhibitors sensitized BRCA1/2 wild-type SUM159 and MDA-MB-231 cells to olaparib, cisplatin, and paclitaxel synergistically (combination index; CI < 1). BAY1816032 significantly increased the radiation sensitization of SUM159 and MDA-MB-231 by olaparib, cisplatin, or paclitaxel at non-toxic concentrations (doses well below the IC50 concentrations). Importantly, the small molecular inhibitor of BUB1 synergistically (CI < 1) sensitized the BRCA mutant TNBC cell line HCC1937 to olaparib. Furthermore, the BUB1 inhibitor significantly increased the radiation enhancement ratio (rER) in HCC1937 cells (rER 1.34) compared to either agent alone (BUB1i rER 1.19; PARPi rER 1.04). The data presented here are significant as they provide proof that inhibition of BUB1 kinase activity sensitizes TNBC cell lines to a PARP inhibitor and radiation, irrespective of BRCA1/2 mutation status. Due to the ability of the BUB1 inhibitor to sensitize TNBC to different classes of drugs (platinum, PARPi, microtubule depolarization inhibitors), this work strongly supports the role of BUB1 as a novel molecular target to improve chemoradiation efficacy in TNBC and provides a rationale for the clinical evaluation of BAY1816032 as a chemosensitizer and chemoradiosensitizer in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI 48202, USA.
- Henry Ford Health + Michigan State University Health Sciences, Detroit, MI 48202, USA.
- Department of Radiology, Michigan State University, East Lansing, MI 48824, USA.
ORCID-Profile: Shyam Nyati
Förderung
- NIH HHS
- Henry Ford Cancer Institute
- Henry Ford Health
- NCI NIH HHS
- NCI R21
- HFHS Research Administration Start up
- HFHS Proposal Development Award
- HFHS-Rad Onc Start Up
Zitieren
APA
Sriramulu, S., Thoidingjam, S., Siddiqui, F., Brown, S. L., Movsas, B., Walker, E., & Nyati, S. (2024). BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy. Biomolecules. https://doi.org/10.3390/biom14060625
Vancouver
Sriramulu S, Thoidingjam S, Siddiqui F, Brown SL, Movsas B, Walker E, et al. BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy. Biomolecules. 2024. doi:10.3390/biom14060625
BibTeX
@article{Sriramulu2024,
author = {Sriramulu, Sushmitha and Thoidingjam, Shivani and Siddiqui, Farzan and Brown, Stephen L and Movsas, Benjamin and Walker, Eleanor and Nyati, Shyam},
title = {BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14060625}
}
EUVIMED